IPM Take
Travel medicine is one of public health’s least dramatic opportunities to prevent hospitalisation. There is no technological mystery here: hepatitis A vaccination works, recommendations exist and risk can often be addressed before someone boards a plane.
Florida’s outbreak shows what happens when that preventive encounter is missed. Genomics then has to reconstruct a transmission story that vaccination might have prevented from becoming a hospital story at all.
Executive Summary
CDC and Florida investigators identified 79 hepatitis A cases associated with travel to Cuba or linked epidemiologically or genomically to the outbreak between June 2024 and February 2026.
Among 249 confirmed hepatitis A cases reported in Florida during the investigation period, 76 patients had recently travelled to Cuba. Three additional cases without documented travel were linked through epidemiological or molecular evidence.
Fifty-seven of the 79 outbreak-associated patients, or 72%, were hospitalised. No deaths were reported. Genetic sequencing showed that 15 of 18 genotyped cases belonged to the same genotype IA outbreak strain, supporting a common epidemiological pattern.
Why it matters
- Clinicians: Travel history should be considered rapidly in patients presenting with compatible hepatitis symptoms, particularly when vaccination status is uncertain.
- Travellers: Hepatitis A vaccination before travel remains the most direct preventive intervention.
- Public-health authorities: Molecular surveillance can connect cases that routine travel histories alone would leave fragmented.
Travel-associated infection can expose a peculiar weakness in otherwise sophisticated health systems. The preventive intervention may be inexpensive, widely available and highly effective, yet the opportunity to use it depends on somebody recognising the risk before departure.
The hepatitis A cases identified in Florida illustrate that gap. More than 30% of confirmed hepatitis A cases reported during the investigation period involved recent travel to Cuba, and molecular epidemiology subsequently connected additional infections to the same outbreak pattern. Almost three quarters of the 79 outbreak-associated patients were hospitalised.
That level of hospital use matters because hepatitis A is vaccine-preventable. Unlike chronic hepatitis B or C, hepatitis A does not establish long-term infection, but disease in adults can be prolonged and severe enough to require hospital care. Prevention before exposure therefore carries value far beyond avoiding several uncomfortable days of illness.
Travel advice, however, reaches people unevenly. Some travellers attend dedicated travel clinics months before departure. Others are visiting relatives, returning frequently to a familiar country or booking travel without any healthcare encounter at all. Familiarity can itself lower perceived risk: a destination may feel like home rather than somewhere that requires “travel medicine.”
That is where routine care can do more. Primary-care records, vaccination histories and discussions triggered by planned travel can identify people who lack hepatitis A protection without requiring every traveller to perceive themselves as medically high-risk.
The Florida investigation also demonstrates the increasingly important role of genomic surveillance. Travel history identified the initial pattern, but sequencing helped show that apparently separate cases belonged to the same epidemiological event. Fifteen of 18 genotyped infections matched the same genotype IA outbreak strain. That level of resolution allows public-health teams to distinguish a real common pattern from coincidence.
Investigators also found that travel was not confined to a single location within Cuba. Among people completing more detailed questionnaires, destinations included Havana and several other provinces. The evidence therefore supported a geographically broader exposure pattern rather than one isolated venue that travellers could simply be told to avoid.
That makes vaccination even more important. When risk is diffuse, behavioural advice has limits. Travellers cannot inspect every food-handling practice or water exposure they encounter. A vaccine places prevention with the traveller rather than asking them to identify an invisible virus in an unfamiliar environment.
The public-health response should remain proportionate. The investigation does not mean every traveller to Cuba will acquire hepatitis A, nor does it justify stigma toward a country or its population. It does justify ensuring that existing recommendations actually reach people who are travelling.
Modern disease surveillance can now sequence viruses, connect infections across counties and reconstruct international exposure after patients become sick.
The cheaper intervention happens before the flight.
